105786-95-6

Basic information

• Product Name: 4,5,6,7-Tetrahydro-3-hydroxy-[1,2,3]oxadiazolo[3,4-a]pyridin-8-ium inner salt
• Synonyms: 4,5,6,7-Tetrahydro-3-hydroxy-[1,2,3]oxadiazolo[3,4-a]pyridin-8-ium inner salt;Tetrahydropyrido[c]sydnone;[1,2,3]Oxadiazolo[3,4-a]pyridin-8-iuM, 4,5,6,7-tetrahydro-3-hydroxy-, inner salt;4,5,6,7-tetrahydro-[1,2,3]oxadiazolo[3,4-a]pyridin-8-iuM-3-olate
• CAS NO: 105786-95-6
• Molecular Formula: C₆H₈N₂O₂
• Molecular Weight: 140.14
• Mol File: 105786-95-6.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4,5,6,7-Tetrahydro-3-hydroxy-[1,2,3]oxadiazolo[3,4-a]pyridin-8-ium inner salt(CAS DataBase Reference)
• NIST Chemistry Reference: 4,5,6,7-Tetrahydro-3-hydroxy-[1,2,3]oxadiazolo[3,4-a]pyridin-8-ium inner salt(105786-95-6)
• EPA Substance Registry System: 4,5,6,7-Tetrahydro-3-hydroxy-[1,2,3]oxadiazolo[3,4-a]pyridin-8-ium inner salt(105786-95-6)

Safety Data

• Hazardous Substances Data: 105786-95-6(Hazardous Substances Data)

Usage

Description

4,5,6,7-Tetrahydro-3-hydroxy-[1,2,3]oxadiazolo[3,4-a]pyridin-8-ium inner salt is a synthetic intermediate with a complex chemical structure, characterized by its tetrahydro, hydroxy, and oxadiazolo-pyridinium features. It plays a significant role in the development of various pharmaceutical compounds due to its unique properties and reactivity.

Uses

Used in Pharmaceutical Industry:
4,5,6,7-Tetrahydro-3-hydroxy-[1,2,3]oxadiazolo[3,4-a]pyridin-8-ium inner salt is used as a synthetic intermediate for the preparation of fused bicyclic heterocycles. These heterocycles are potent and selective 5-HT2A receptor antagonists, which are crucial in the treatment of insomnia. The compound's ability to modulate the serotonin receptor system makes it a valuable asset in the development of novel therapeutic agents for sleep disorders.
Additionally, 4,5,6,7-Tetrahydro-3-hydroxy-[1,2,3]oxadiazolo[3,4-a]pyridin-8-ium inner salt is used as a synthetic intermediate for the synthesis of β-lactamase inhibitors. These inhibitors are essential in the development of antibiotics, as they help to overcome bacterial resistance to β-lactam antibiotics, such as penicillins and cephalosporins. By inhibiting the enzyme β-lactamase, which is responsible for breaking down these antibiotics, the compound contributes to the effectiveness of these drugs in treating bacterial infections.

Upstream product

• 3105-95-1 pipecolinic acid 
• 30310-83-9 N-nitroso-L-pipecolic acid 
• 98303-20-9 1-(tert-butoxycarbonyl)piperidine-2-carboxylic acid 
• 132910-79-3 (+/-) methyl N-tert-butyloxycarbonyl 2-piperidinecarboxylate 
• 4043-87-2 pipecolic Acid 
• 4515-18-8 1-nitroso-piperidine-2-carboxylic acid 

Downstream Products

• 1338582-24-3 2-(4-fluorophenyl)-3-iodo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine 
• 1338580-85-0 N-{4-[2-(4-Fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl]pyridin-2-yl}propanamide 
• 118055-06-4 4,5,6,7-Tetrahydropyrazolo<1,5-a>pyridin-3-carbonsaeureethylester 
• 307313-04-8 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-2-carboxylic acid chloride 
• 307307-97-7 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine-3-carboxylic acid 
• 1367714-09-7 C₂₀H₂₄F₂N₄O 
• 1367714-07-5 C₂₀H₂₄F₂N₄O 
• 307313-03-7 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine-2-carboxylic acid 
• 1338582-12-9 2-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine 
• 1338580-81-6 2-(4-Fluorophenyl)-3-(pyridin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine 
• 1161076-52-3 3-(2-chloro-4-pyrimidinyl)-2-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine 
• 1161076-87-4 2-(4-fluorophenyl)-4,5,6,7-tetrahydro-3-[2-(methylthio)-4-pyrimidinyl]pyrazolo[1,5-a]pyridine 
• 1160614-72-1 2-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine 
• 307307-84-2 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine-2-carboxylic acid ethyl ester 

Relevant articles and documents

Design, synthesis and biological evaluation of ring-fused pyrazoloamino pyridine/pyrimidine derivatives as potential FAK inhibitors

We report herein the synthesis of novel ring-fused pyrazoloamino pyridine/pyrimidine derivatives as potential FAK inhibitors and the evaluation of pharmaceutical activity against five cancer cell lines (MDA-MB-231, BXPC-3, NCI-H1975, DU145 and 786O). Generally, the majority of compounds displayed strong anti-FAK enzymatic potencies (IC50 1 nM) and could effectively inhibit several class of cancer cell lines within the concentration of 3 μM in comparison with GSK2256098 as a reference. Among them, compound 4o is considered to be the most effective due to high sensitivity in antiproliferation. In culture, 4o could not only inhibit FAK Y397 phosphorylation in MDA-MB-231 cell line, but also trigger apoptosis in a dose-dependent manner. Furthermore, computational docking analysis also suggested that 4o and TAE-226 displayed the similar interaction with FAK kinase domain.

Focal adhesion kinase inhibitor and use

The invention belongs to the field of medicines, relates to a focal adhesion kinase inhibitor and use, in particular relates to a novel focal adhesion kinase inhibitor compound, or stereoisomers, geometric isomers, tautomers, oxynitrides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, further relates to the use of the compound and pharmaceutical compositions as medicines, in particular the use of the compound and pharmaceutical compositions in manufacture of medicines for treatment or prevention of cancer, pulmonary hypertension, and pathological angiogenesis-related diseases.

Identification of fused bicyclic heterocycles as potent and selective 5-HT2A receptor antagonists for the treatment of insomnia

A series of fused bicyclic heterocycles was identified as potent and selective 5-HT2A receptor antagonists. Optimization of the series resulted in compounds that had improved PK properties, favorable CNS partitioning, good pharmacokinetic properties, and significant improvements on deep sleep (delta power) and sleep consolidation.